Search | Clinical Trials Finder

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions: Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome
Interventions: Decitabine, Clofarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: Decitabine, Carboplatin, Paclitaxel, Selinexor; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 280
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more

Conditions: Refractory Acute Leukemia, Pediatric Relapsed
Interventions: Ziftomenib, Venetoclax, Azacitidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: ATRN-119, Decitabine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions: AMG 397, Dexamethasone, Azacitidine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions: gilteritinib, azacitidine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 7 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Olutasidenib; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Lemzoparlimab, Azacitidine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Birmingham, Alabama • Louisville, Kentucky • Boston, Massachusetts + 5 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-486; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: New York, New York • Cleveland, Ohio • Houston, Texas + 1 more

Conditions: Leukemia, Myeloid, Acute
Interventions: DCLL9718S, Azacitidine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: Azacitidine, Durvalumab; Drug · Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Azacitidine, Daratumumab, Dexamethasone; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Filgrastim, Cyclosporine, Decitabine, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions: chemotherapy, venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 25 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Myeloproliferative Neoplasm
Interventions: Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg; Drug
Lead sponsor: Joseph Jurcic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelodysplastic Syndrome, Myelodysplastic Syndromes
Interventions: GSK2879552, Azacitidine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: Azacitidine, Pre-DLI Salvage Chemotherapy, Donor Leukocyte Infusion (DLI); Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Acute Myeloid
Interventions: Decitabine, Vorinostat, Fludarabine, Cytarabine, Filgrastim, Sorafenib; Drug
Lead sponsor: Michael Burke; Other
Eligibility: 1 Year to 25 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Milwaukee, Wisconsin

Conditions: Myelodysplastic Syndrome
Interventions: decitabine (5-aza-2'deoxycytidine); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 24
States / cities: Berkeley, California • Duarte, California • Escondido, California + 17 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: decitabine, romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions: Dacogen; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Epigenetic Reprogramming in Relapse AML

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)